These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 9169309

  • 21. Do noradrenaline and serotonin differentially affect social motivation and behaviour?
    Dubini A, Bosc M, Polin V.
    Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S49-55; discussion S71-3. PubMed ID: 9169310
    [Abstract] [Full Text] [Related]

  • 22. Depersonalization-derealization syndrome induced by reboxetine.
    Khazaal Y, Zullino DF.
    Swiss Med Wkly; 2003 Jul 12; 133(27-28):398-9. PubMed ID: 12947529
    [Abstract] [Full Text] [Related]

  • 23. Predicting response: noradrenaline reuptake inhibition.
    Montgomery SA.
    Int Clin Psychopharmacol; 1999 May 12; 14 Suppl 1():S21-6. PubMed ID: 10468325
    [Abstract] [Full Text] [Related]

  • 24. A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder.
    Pancheri P, Scapicchio P, Chiaie RD.
    Int J Neuropsychopharmacol; 2002 Dec 12; 5(4):287-94. PubMed ID: 12466028
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
    Fava M, McGrath PJ, Sheu WP, Reboxetine Study Group.
    J Clin Psychopharmacol; 2003 Aug 12; 23(4):365-9. PubMed ID: 12920412
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group.
    Versiani M, Amrein R, Stabl M.
    Int Clin Psychopharmacol; 1997 Jul 12; 12(4):183-93. PubMed ID: 9347378
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.
    Langworth S, Bodlund O, Agren H.
    J Clin Psychopharmacol; 2006 Apr 12; 26(2):121-7. PubMed ID: 16633139
    [Abstract] [Full Text] [Related]

  • 35. Chairman's overview. The place of reboxetine in antidepressant therapy.
    Montgomery SA.
    J Clin Psychiatry; 1998 Apr 12; 59 Suppl 14():26-9. PubMed ID: 9818628
    [Abstract] [Full Text] [Related]

  • 36. A placebo- and imipramine-controlled study of paroxetine.
    Cohn JB, Crowder JE, Wilcox CS, Ryan PJ.
    Psychopharmacol Bull; 1990 Apr 12; 26(2):185-9. PubMed ID: 2146697
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. A double-blind controlled clinical trial comparing fluvoxamine with imipramine.
    Guelfi JD, Dreyfus JF, Pichot P.
    Br J Clin Pharmacol; 1983 Apr 12; 15 Suppl 3(Suppl 3):411S-417S. PubMed ID: 6407501
    [Abstract] [Full Text] [Related]

  • 39. Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals.
    Crawford AA, Lewis S, Nutt D, Peters TJ, Cowen P, O'Donovan MC, Wiles N, Lewis G.
    Psychopharmacology (Berl); 2014 Aug 12; 231(15):2921-31. PubMed ID: 24525810
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.